Imunon (IMNN) Life Sciences Investor Forum summary

Key presentations and clinical insights

• Presented phase II data for IMNN-001, a DNA-based immunotherapy targeting advanced ovarian cancer, showing a 13-month overall survival improvement over standard chemotherapy and a favorable safety profile without dose-limiting toxicities or cytokine release syndrome.

• Phase II results were highlighted at the 2025 ASCO meeting and published in the Journal of Gynecologic Oncology, receiving strong interest from the medical community and potential principal investigators globally.

• The phase III trial, OVATION 3, mirrors the phase II design but includes enhancements such as biomarker stratification, quality of life measures, and in-house manufacturing to improve cost efficiency and trial consistency.

• Enrollment for phase III is underway, with the first patient visit targeted for the current quarter and interim analysis expected one to one and a half years after full enrollment.

• Recent financing with warrants could generate up to $10 million in gross proceeds, providing cash runway into the first quarter of next year.

Strategic and industry context

• IMNN-001 is positioned as the only immunotherapy in late-stage development for frontline ovarian cancer, addressing a high unmet need where immune checkpoint inhibitors have failed to improve overall survival.

• The company’s in-house manufacturing of active pharmaceutical ingredients has improved yield, quality, and cost control, with FDA approval for clinical use.

• The PlaCCine vaccine platform, a derivative of TheraPlas, will advance through partnerships, with recent six-month durability data to be presented at an international vaccine conference.

• The phase III trial is designed for potential early stopping in the HRD-positive subgroup, enabling fast-track submission for full approval if successful.

• The company anticipates high patient capture rates due to being the only trial enrolling newly diagnosed patients in this indication.